Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Therapy Cells, Inc. (TCEL)

TCEL RSS Feed
Add TCEL Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, ChannelTrader, surfkast, MIKEY501, BINARY DECISION
Search This Board:
Last Post: 11/23/2014 6:24:34 PM - Followers: 372 - Board type: Free - Posts Today: 5

 



TCEL  Therapy Cells, Inc.






THE  FOLLOWING INFO CAN BE VERIFIED AT :  http://www.otcmarkets.com/stock/TCEL/quote

 


Market value as of June  06 2014
$719,086



Shares outstanding as of  August 7,2014
583,350,001 est



Float as of August 7, 2014
463,151,401 est


A/S
1,500,000,000 a/o August 7,2014

 
SECURITY NOTES: REVERSE SPLIT HISTORY
  • Capital Change=shs decreased by 1 for 1000 split Pay date=05/28/2010.
    Capital Change=shs decreased by 1 for 1500 split. Pay date=09/19/2011.



FINANCING THROUGH STOCK ISSUSANCE

The number of shares sold; 
Date Offered Sold/Redeemed Price Paid Desciption of transactions
01-Jan-12 1,037,359 1,037,359 $0.000000 $0 Brought forward
28-Mar-12 76,260,000 76,260,000 $0.000100 $7,626 Conversion of 76,260 Series E Preferred stock
28-Feb-13 12,300,000 12,300,000 $0.001000 $12,300Redemption of $12,300 of Convertible Notes
20-Jun-13 2,000,000 2,000,000 $0.001000 $2,000 Redemption of $2,000 of Convertible Notes
25-Jun-13 2,000,000 2,000,000 $0.001000 $2,000 Redemption of $2,000 of Convertible Notes
09-Aug-13 2,200,000 2,200,000 $0.001000 $2,200 Redemption of $2,200 of Convertible Notes
13-Aug-13 750,000 750,000 $0.001000 $750 Payment of $750 for services
16-Aug-13 750,000 750,000 $0.001000 $750 Payment of $750 for services
03-Sep-13 8,250,000 8,250,000 $0.001000 $8,250 Redemption of $8,250 of Convertible Notes
10-Sep-13 5,000,000 5,000,000 $0.001000 $5,000 Redemption of $5,000 of Convertible Notes
11-Feb-14 6,240,000 6,240,000 $0.000100 $624 Redemption of $624 of Convertible Notes
14-Feb-14 6,563,800 6,563,800 $0.000100 $656 Redemption of $656 of Convertible Notes
25-Feb-14 6,907,680 6,907,680 $0.000100 $691 Redemption of $691 of Convertible Notes
05-Mar-14 7,260,000 7,260,000 $0.000100 $726 Redemption of $726 of Convertible Notes
13-Mar-14 7,643,300 7,643,300 $0.000100 $764 Redemption of $764 of Convertible Notes
20-Mar-14 8,043,450 8,043,450 $0.000100 $804 Redemption of $804 of Convertible Notes
31-Mar-14 8,027,206 8,027,206 $0.000100 $803 Redemption of $803 of Convertible Notes
01-Apr-14 8,043,450 8,043,450 $0.000100 $804 Redemption of $804 of Convertible Notes
14-Apr-14 8,870,000 8,870,000 $0.000100 $887 Redemption of $887 of Convertible Notes
18-Apr-14 9,333,900 9,333,900 $0.000100 $933 Redemption of $933 of Convertible Notes
22-Apr-14 9,333,900 9,333,900 $0.000100 $933 Redemption of $933 of Convertible Notes
22-Apr-14 10,000,000 10,000,000 $0.000100 $1,000 Redemption of $1,000 of Convertible Notes
24-Apr-14 10,000,000 10,000,000 $0.001000 $10,000Redemption of $10,000 of Convertible Notes
06-May-14 10,000,000 10,000,000 $0.000100 $1,000 Redemption of $1,000 of Convertible Notes
06-May-14 10,000,000 10,000,000 $0.000100 $1,000 Redemption of $1,000 of Convertible Notes
06-May-14 10,000,000 10,000,000 $0.000077 $767 Redemption of $767 of Convertible Notes
07-May-14 10,000,000 10,000,000 $0.000100 $1,000 Redemption of $1,000 of Convertible Notes
08-May-14 9,400,000 9,400,000 $0.000100 $940 Redemption of $940 of Convertible Notes
08-May-14 10,000,000 10,000,000 $0.000100 $1,000 Conversion of 10,000 Series E Preferred stock
09-May-14 10,800,000 10,800,000 $0.000100 $1,080 Redemption of $1,080 of Convertible Notes
19-May-14 10,800,000 10,800,000 $0.000100 $1,080 Redemption of $1,080 of Convertible Notes
21-May-14 11,370,450 11,370,450 $0.000100 $1,137 Redemption of $1,137 of Convertible Notes
23-May-14 11,370,450 11,370,450 $0.000100 $1,137 Redemption of $1,137 of Convertible Notes
28-May-14 10,000,000 10,000,000 $0.000100 $1,000 Redemption of $1,000 of Convertible Notes
03-Jun-14 14,488,000 14,488,000 $0.000100 $1,449 Redemption of $1,449 of Convertible Notes
03-Jun-14 14,500,000 14,500,000 $0.000100 $1,450 Redemption of $1,450 of Convertible Notes
09-Jun-14 20,000,000 20,000,000 $0.001000 $20,000Redemption of $20,000 of Convertible Notes
10-Jun-14 18,800,000 18,800,000 $0.000100 $1,880 Redemption of $1,880 of Convertible Notes
12-Jun-14 18,838,000 18,838,000 $0.000100 $1,884 Redemption of $1,884 of Convertible Notes
18-Jun-14 19,800,000 19,800,000 $0.000100 $1,980 Redemption of $1,980 of Convertible Notes
25-Jun-14 20,860,600 20,860,600 $0.000100 $2,086 Redemption of $2,086 of Convertible Notes
26-Jun-14 21,900,000 21,900,000 $0.000100 $2,190 Redemption of $2,190 of Convertible Notes
479,741,545 
Private offering stockholder information:
Date Holding Current % Stockholder Benficial owner or Controller
28-Mar-12 10,000,000 Nejo Ltd
 10,000,000 P Casey
 10,000,000 G Green
 1,000,000 I Shaw
 6,900,000 Anchor Financial
 6,200,000 Tiffany Asset Group
 4,900,000 Alpha Brilliant
 5,000,000 Kars Capital
 5,960,000 E Sexsmith
 5,500,000 Macau Consultants
 5,000,000 Convergent Capital
 5,800,000 Tower Financial
01-Mar-13 4,100,000 Freeport Securities
 4,200,000 Windsong Investments
07-Mar-13 250,000 Macca Holdings
 1,250,000 M Bergman
 1,250,000 Kaufman Associates
25-Apr-13 500,000 Macca Holdings
 750,000 Greenwich Financial
20-Jun-13 2,000,000 Macca Holdings
25-Jun-13 2,000,000 iNet Holdings
09-Aug-13 1,000,000 Greenwich Financial
 1,200,000 Joseph Fragala
13-Aug-13 750,000 iNet Holdigns LLC
16-Aug-13 750,000 Macca Holdings LLC
03-Sep-13 8,250,000 iNet Holdigns LLC
10-Sep-13 5,000,000 Appinero LLC
11-Feb-14 6,240,000 36% Redwood Management Gary Rogers and John Denobile, 16850 Collins Ave # 
# 112-341, Sunny Isles, Florida 33160
14-Feb-14 6,563,800 Redwood Management
25-Feb-14 6,907,680 Redwood Management
05-Mar-14 7,260,000 Redwood Management
13-Mar-14 7,643,300 Redwood Management
20-Mar-14 8,043,450 Redwood Management
31-Mar-14 8,027,206 20% Bou Trust Alan Uryniak (Trustee), 9 Wayne Street, Montvale, New 
 Jersey 07645
01-Apr-14 8,043,450 Redwood Management
14-Apr-14 8,870,000 Redwood ManagementOTC Markets Group Inc. 
OTC Pink Basic Disclosure Guidelines (v1.0 January 3, 2013) Page 6 of 11
18-Apr-14 9,333,900 Bou Trust
22-Apr-14 9,333,900 Redwood Management
 10,000,000 Alpha Brilliant Limited
24-Apr-14 10,000,000 Gold Coast Capital Inc
06-May-14 10,000,000 Freeport Securities
 10,000,000 Theman Holdings Inc
 10,000,000 Windsong Investments LTD
07-May-14 10,000,000 Anchor Financial Inc
08-May-14 9,400,000 Redwood Management
 10,000,000 Standard Trade Inc
09-May-14 10,800,000 Bou Trust
19-May-14 10,800,000 Redwood Management
21-May-14 11,370,450 Bou Trust
23-May-14 11,370,450 Redwood Management
28-May-14 10,000,000 Gold Coast Capital Inc
03-Jun-14 14,488,000 Redwood Management
 14,500,000 Bou Trust
09-Jun-14 20,000,000 Nobilis Consulting
10-Jun-14 18,800,000 Redwood Management
12-Jun-14 18,838,000 Bou Trust
18-Jun-14 19,800,000 Redwood Management
25-Jun-14 20,860,600 Redwood Management
26-Jun-14 21,900,000 Bou Trust
 478,704,186 
Redwood Management LLC, BOU Trust, Alpha Brilliant, Anchor Financial, Freeport Securities, Tower Financial and 
Windsong Investments all hold reserve options on Common Stock purchased through the redemption of Convertible 
Notes. As at June 30, 2014 their reserve accounts and stock draw-downs were as follows:
 Options Converted Balance
Alpha Brilliant 100,000,000 10,000,000 90,000,000 
Anchor Financial 100,000,000 10,000,000 90,000,000 
BOU Trust 250,000,000 94,769,556 155,230,444 
Freeport Securities 100,000,000 10,000,000 90,000,000 
Redwood Mgment 300,000,000 174,424,630 125,575,370 
Tower Financial 100,000,000 - 100,000,000 
Windsong Inv 40,000,000 10,000,000 30,000,000 
Total 990,000,000 309,194,186 680,805,814 C
All stockholdings relate to purchases and transfers registered with our Transfer Agents up to and including June 30, 
2014.


Industry Classification:
Medical Labratories, Development stage company

Check here for today's  regSHO standing:  (failed to deliver shares)

http://www.nasdaqtrader.com/trader.aspx?id=RegSHOThreshold


http://otcshortreport.com/index.php?index=TCEL&action=view#.U445LMpOXF8






COMPANY CONTACT INFO:
500 Hazelwood Rd
Venice, Florida
34293
telephone 44 173 246  0224 (A British telephone number)
email :   info@therapycells.com

 
INFORMATION ON 500 HAZLEWOOD ROAD


500 Hazelwood Rd, Venice, FL 34293
4 beds, 2 baths, 1,795 sqft


Sold: $150,400

Sold on 02/24/14

Zestimate®: $153,291



https://www.google.com/maps/search/500+HAZELWOOD+RD+VENICE+FLORIDA+BUSINESSES/@27.072729,-82.408377,3a,75y,173.26h,65.63t/data=!3m4!1e1!3m2!1s52b0j1-hpJ_u6aiE_Q4bDA!2e0





>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Aunt Bee's Services






OPEN NOW

Today7:30 am - 4:30 pm



500 Hazelwood Road,

Venice, FL 34293

(941) 234-3013



https://www.facebook.com/pages/Aunt-Bees-Services/1434007090169104?sk=info

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

0435150039 - VODRAZKA DAVID VODRAZKOVA EMMA
Address:
VODRAZKA DAVID VODRAZKOVA EMMA
HARDING BARRIE

500 HAZELWOOD RD
VENICE FL 34293


http://sarasotataxcollector.governmax.com/collectmax/collect30.asp  
 

Business Description

 

What is Cell Therapy?

Discovered by Dr Casey and Dr Fry, the success of Cell Therapy technology lies in its simplicity. Previously it was believed that once mature, cells were no longer capable of dividing. As a result, many specialists have concentrated on stem-cell research (trying to train one type of cell to become another type of cell), for example trying to get a stem-cell to become a tendon cell. In practice this theory hasn’t been completely successful to-date, with previous attempts to heal tendons resulting in the formation of scar tissue.

Moving completely away from stem-cell theory, Dr Casey and Dr Fry’s own theory of “spatial compaction” is the basis for their revolutionary discovery, dubbed Cell Therapy.

Spatial compaction accepts that cells in their natural environment reach a point where they effectively “fill the skin they’re in” and therefore do not have space to divide any further. However, it surmises that if they were removed from their environment and cultured, they could be induced to start dividing again and become ‘therapy cells.’

In simple terms Dr Casey explains, “Mature cells don’t actually stop, they just go on pause because they don’t have space to keep dividing. It’s a bit like a goldfish – put it in a small bowl and it’ll grow into a small fish, put it in a large pond and it’ll continue to grow.”

Focussing only on the adult cell that is dedicated to its role, Cell Therapy technology involves taking a very small sample of the target tissue. The cells are then grown in sterile laboratory conditions with millions of new cells being produced. These new cells are then transplanted back into the damaged area where they effectively rebuild the damaged tissue.
 

Proven Success

So far Cell Therapy has been successfully tested on three horses that have returned to competition with other treated horses waiting in the wings.

If Cell Therapy continues to be as successful as it currently is, the short-term implications are huge for the racing industry. With the ability to bank healthy cells for future restorative use, keeping winning horses in the race for longer will become a realit

 



Therapy Cells has developed a novel and highly efficient method of growing tendon and articular cartilage for auto transplantation into individual, affected patients.  Our company has developed new cell theory that dispenses with the notion that cells can not divide once they are fully mature.  We have shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory.

The need for tissue and organ repair is growing. This is due to the continual growth of our population, coupled with individual needs to maintain good health. And, as our population grows, so does the number of older people seeking to maintain optimal activity levels.


 

The company’s new approach to cell growth has already been applied to the repair of tendons and joints. The technology has also been applied to the re-growth of pancreas and heart tissue. Rejection does not occur as the new cells are from that individual and are recognised by the body as non foreign. It is our belief that this new method of cell growth will be successfully used for cell and organ repair in many parts of the human body.
 


For more information, please contact:

info@therapycells.com
info@kumeu.com
 

 

 

 

Technology

Therapy Cell has developed a methodology that allows adult cells to divide and grow in controlled laboratory conditions.  These new cells can then be used for transplantation back to damaged tissue to enact tissue and organ healing.

To date, the technology has been used for the growth and transplantation of:

  1. Tendons and ligaments
    and
    Articular cartilage

We have also applied this technology to successfully grow pancreatic cells, for treatment of diabetes, and cardiac cells for the treatment of heart disease, as well as other cell types from many other tissues.

Therapy Cells has shown that given the right culture conditions, these cell types can be grown into  millions of new cells, and then successfully transplanted back into the injured tissue of the individual who has donated the cells, leading to tissue repair with one's one cells.

 


Cartilage cells grown in vitro

EquineCartilage1.jpgEquineCartilage2.jpgEquineCartilage3.jpgEquineCartilage4.jpg

                                                                                                                    Figure 1                                                 Figure 2                                                           Figure 3                                                         Figure 4
 


The company

Therapy Cells Inc (2011)  will bring this transformation technology for tendon repair  to the human market.
 

Dr. Patrick (Paddy) J Casey, BVSc, PhD, MRCVS

Dr. Casey is a pre eminent scientist who, at the age of 25, headed up his own University research programme based at Australasia’s leading medical college, the Faculty of Medical and Health Sciences, University of Auckland.  He has been founder and director of a number of companies that are successful on the national and international stage. He has a reputation for being a highly original thinker who knows how to achieve full implementation of his projects. Dr. Casey travels extensively around the world where he collaborates and consults with a number of top academic minds in relevant fields. He is also associated with a number of top academic institutions.  His contact with leaders in various fields has lead to major scientific collaborations at his young age.

DSC00804.JPG

more information about him:

http://www.voorjaarsdagen.org/index.php?option=com_content&view=article&id=232:cv-dr-pa


LINK TO A MEDICAL PAPER ON STEM CELL MEDICINE PREPARED IN PART BY DR CASEY: JANUARY 2013:

http://www.jbc.org/content/288/11/7986.abstract



 


 

Mr. Garry Green, BCom

Mr Green left a successful accountancy career to follow his entrepreneurial aspirations.  He has been very successful in a variety of business forums and owns a number of diverse and successful companies.  Garry is a director on boards of leading New Zealand companies, and has been a great organizational asset to Therapy Cell.

 

 

 




http://www.horsetalk.co.nz/news/2012/03/017.shtml#ixzz2rfM3niy8
Reuse: You may use up to 20 words and link back to this page. Other reuse not permitted
Follow us: @HorsetalkNZ on Twitter | Horsetalk on Facebook
 
 
 

 

 

Revolutionary science restores horse's Olympic hopes

 

March 2, 2012

 

Two years ago, Angelli, a grand prix showjumping horse from Southern California, was facing retirement or, at worst, euthanasia. His career as a contender for the 2012 Olympic Games was in tatters.

 


Harley Brown and Angelli.
Just the previous weekend, he and his international rider and trainer, Harley Brown of Australia, had been unable to compete in a major Californian show, as the previously grand prix level show jumper could not clear even the lowest of jumps.

Then a phone call was made to an internationally recognised veterinarian and scientist who travels the world as a consultant from New Zealand.

Three days later, Dr Patrick Casey arrived with his ultrasound machine and, after examining Angelli, gave Harley the heartbreaking news.

"He's torn his hind tendon badly, sort of shredded it," Casey explained.

Tendon injuries can be career-ending for horses - only 5 to 15 per cent of those with damaged tendons ever make it back to competition.

Casey explained a revolutionary tendon treatment that had already been shown to get 85 per cent of horses with torn tendons back to full competition.

It involves taking about 100 tendon cells from the injured horse without causing any harm to the animal.

Using a patented procedure, 20 to 40 million tendon cells are then grown in an incubator and transplanted back to the site of injury.

Brown and Angelli's owner, Mark Harryman, knew that unless they had a go, all hope was lost for their horse's future jumping career.

The treatment worked. Not only is Angelli's shredded tendon healed, but he has a chance to be selected to jump at the London Olympics for Australia with Harley Brown.

"We just could not have ever imagined how well this science works," Brown said.

"I have never heard of a horse coming back from this injury, let alone being competitive at the highest level. It's just like a dream."

Late in March, Casey, Brown and Harryman will be reunited in Wellington, Florida, where Angelli's American preparation will end and he will fly to Europe for more pre-Olympic trials.

It is fair to say that Dr Casey "wouldn't miss it for the world and, considering where I come from, wouldn't mind a cold one to celebrate."

Last year, Casey set up a public company in the United States called Therapy Cells, Inc.

It holds the exclusive technology that allows adult cells from a specific tissue, such as an Achilles tendon, to grow again from individual cells, to enact repair and regeneration of that tissue, effectively bypassing the need for stem cell treatment.

The company has developed a novel and highly efficient method of growing tendons and articular cartilage for auto transplantation into injured horses or people.

Of real interest to veterinarians worldwide is the clinical success in horses.

Sixty-six horses have been treated with therapy cells to date. The data accumulated from horses will ultimately have direct application in seeking Food and Drug Administration (FDA) approval for human use.

The company's technique dispenses with the traditional notion that cells cannot divide once they are fully mature.

 


Dr Patrick Casey
Casey has shown that adult cells, given the right environment, can be induced to divide in the laboratory. These newly grown cells can then be put back into damaged tissue in the body, to enact tissue and organ healing.

"With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order has direct application for human tendon repair," Casey says.

"An initial valuation of $US30 million for our science and technology has been appraised.

"FDA approval for clinical use of this technology in the human, will likely increase this factor by at least 10 times."

Casey graduated as a veterinarian from Massey University in 1988, at the age of 21, and then from the University of California in 1992 with a Doctor of Philosophy in Comparative Pathology).

During his time in the United States he also completed an equine surgical internship at Hagyard-Davidson and McGee, in Lexington, Kentucky, followed by a three-year residency program in Equine Reproduction, with a minor in Equine Medicine at UC Davis.

In the early 1990s he received a post-doctoral fellowship from the Equine Research Laboratory at the University of California, which allowed him to set up with the late, world renowned, Professor Liggins at the University of Auckland, New Zealand.

 


Harley Brown and Angelli in June 2011:
 




Therapy Cells, Inc Receives USA Patent Granted for Revolutionary Cell Therapy

ACCESSWIRE via CMTX - Tue Aug 20, 9:56AM CDT
 
 
         
         

CHEYENNE, WY- (ACCESSWIRE - August 20,2013) - Therapy Cells Inc (OTC Pink: TCEL) announces that on 13 February 2013, US patent US 11/702,895 was awarded to renowned scientist Dr Patrick Casey and Transplantation Ltd, for his transformational cell therapy, exclusively licensed to Therapy Cells Inc for use in human applications.

This revolutionary science dispenses with the traditional notion that cells cannot divide once they are fully mature. Dr Casey has shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory. These new cells can then be used for transportation back to damaged tissue in the body, to enact tissue and organ healing.

The research team headed by Dr Casey has to date treated more than 80 horses including thoroughbreds, standardbreds, polo ponies and horses at the highest level of equestrian competition.

"With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order have human applications in human tendons," Dr Casey says. "An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in humans, will likely increase this factor by at least 10 times." The horse is an FDA approved model species for athletic injuries.

Dr Casey is a Veterinary graduate from Massey University (BVSc, 1988), and graduate from the University of California in 1992 with a Doctor of Philosophy (PhD, Comparative Pathology). During his time in the United States he also completed an Equine Surgical Internship at Hagyard-Davidson and McGee, Lexington, Kentucky, followed by a three year residency programme in Equine Reproduction, with a minor in Equine Medicine at UC Davis. In 1992, 1993, and 1994 he received a post-doctoral fellowship from the Equine Research Laboratory at the University of California, which allowed him to set up with the late, world renowned, Professor Liggins at the University of Auckland, New Zealand.

Since 2011, Dr Casey has been chief scientific consultant to a public company in the USA - Therapy Cells Inc (TCEL on the OTC Market).

This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells from a specific tissue (e.g. Achilles tendon) to grow again from an individual to enact repair and regeneration of that tissue, effectively by-passing the need for Stem Cell treatment.

"The financial and curative potential of this biotechnology platform is immediately obvious," states Dr Casey. "When we talk about regenerative procedures, the ability to rejuvenate tissues and organs with cultivated natural cell therapy, it's easy to understand how enormous the opportunity and the impact will be. The awarding of this US Patent for our transformational science is a significant milestone in the steps we have been taking to get our therapies to market."

Contact:

Contact: Patrick Casey

Company Headquarters:

1712 Pioneer Ave., Ste 101
Cheyenne, Wyoming
82001

Phone (USA)  001 702 666 8570

Email: info@therapycells.com

Website ??????????: http://www.therapycells.com/

THIS IS THE MESSAGE ON THAT SITE:


 

Therapy Cells (2000) Ltd
A New Zealand Company
NOT: TCel Inc. All enquires for that please refer to their CEO John Meredithjwsmeredith@aol.com
 
 Therapy Cells (2000) Ltd Commercializing
USPatent #8,372,644
Time to expiry of this patent
21.2 Years

 



 

Charting

 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TCEL
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#20744  Sticky Note The Company’s business operations consist of doing business BINARY DECISION 11/21/14 12:21:39 PM
#19908  Sticky Note DD UPDATE: surfkast 09/30/14 05:42:37 PM
#20789   current O/S = 479,741,545 BINARY DECISION 11/23/14 06:24:34 PM
#20788   chart looks strong for heavy bounce BINARY DECISION 11/23/14 01:41:17 PM
#20787   stockcharts.com/c-sc/sc?s=tcel&p=D&yr=1&mn=0&dy=0&i=p95768092408&r=1952[/ mick 11/23/14 12:53:06 PM
#20786   Agreed, your hot this year sharky. Bring it $$$$ STOCK_MOMO 11/23/14 12:40:50 PM
#20785   AS 2.9 billion but Meredith hasn't diluted in Months.. BINARY DECISION 11/23/14 10:26:34 AM
#20784   oh yea BINARY DECISION 11/22/14 11:54:41 PM
#20783   buying whats left at 6 monday BINARY DECISION 11/22/14 11:51:21 PM
#20782   Strength building, strong hands holding and adding. :) sharky 11/22/14 11:37:54 PM
#20781   Supposed to get in before the news ;) SK3 11/22/14 04:55:12 AM
#20780   fine with me if they fill me. mc6102 11/22/14 12:58:43 AM
#20779   or maybe we will come back to 4's pitacorp 11/21/14 10:13:33 PM
#20778   TCEL nice action today. STOCK_MOMO 11/21/14 05:54:35 PM
#20777   #5 on breakout boards..... sharky 11/21/14 05:13:48 PM
#20776   lol sharky 11/21/14 05:11:54 PM
#20775   No crystal ball but when this one has Chyna9 11/21/14 04:25:05 PM
#20774   Looking good for monday. dreamer91 11/21/14 04:14:40 PM
#20773   What is the O/S? (By the way, a lelio 11/21/14 03:58:42 PM
#20772   It is just 5M shares. I would take THEGOOGLE5 11/21/14 03:44:43 PM
#20771   Move those .0006's :) sharky 11/21/14 03:33:03 PM
#20770   911 block signal BINARY DECISION 11/21/14 02:59:33 PM
#20769   psychological wall at 001 BINARY DECISION 11/21/14 02:58:27 PM
#20768   Pressure building...... sharky 11/21/14 02:56:53 PM
#20767   So thin.... After 6s it on to Tbone88 11/21/14 02:44:32 PM
#20766   I think we've thought that for a few Chyna9 11/21/14 02:42:43 PM
#20765   next week the chase begins BINARY DECISION 11/21/14 02:22:23 PM
#20764   well, nearly all the jumps happen in one mc6102 11/21/14 02:20:19 PM
#20763   near term BINARY DECISION 11/21/14 02:19:01 PM
#20762   GREAT! MAYBE SEE .001! surfkast 11/21/14 02:18:10 PM
#20761   bids rolling in now TCEL BINARY DECISION 11/21/14 02:09:49 PM
#20760   FREE PLUS = 1/2 PRICE! surfkast 11/21/14 02:06:29 PM
#20759   oh yea and the NSS BINARY DECISION 11/21/14 01:56:02 PM
#20758   Its amazing how active this stock has been dreamer91 11/21/14 01:52:30 PM
#20757   $hit..better than red but i wanted more 5's BINARY DECISION 11/21/14 01:42:36 PM
#20756   There - 5s destroyed. GoldMiner 11/21/14 01:39:14 PM
#20755   yea i really wouldn't mind they threw up BINARY DECISION 11/21/14 01:37:01 PM
#20754   5s about to fall. Only about 800K left GoldMiner 11/21/14 01:35:54 PM
#20753   call the crew BINARY DECISION 11/21/14 01:25:42 PM
#20752   nibbles testing the L2 walls BINARY DECISION 11/21/14 01:23:25 PM
#20751   bad idea BINARY DECISION 11/21/14 01:05:55 PM
#20750   WAITING ON NEWS BEFORE i JUMP...... surfkast 11/21/14 12:52:34 PM
#20749   4's are best you can hope for BINARY DECISION 11/21/14 12:49:09 PM
#20748   In October 2013 we had to cease surfkast 11/21/14 12:39:07 PM
#20747   yes picked up small load to add my stack BINARY DECISION 11/21/14 12:37:43 PM
#20746   In the meantime there is always an unlimited THEGOOGLE5 11/21/14 12:32:57 PM
#20745   confirmation filings are going to have a couple surprises gentlemen BINARY DECISION 11/21/14 12:27:48 PM
#20744   The Company’s business operations consist of doing business BINARY DECISION 11/21/14 12:21:39 PM
#20743   Meredith waiting one more week to file BINARY DECISION 11/21/14 12:13:33 PM
#20742   http://stockcharts.com/c-sc/sc?s=TCEL&p=D&b=5&g=0&i=t97885137332&r=14165897 BINARY DECISION 11/21/14 12:10:54 PM
#20741   anyone know current RSI? I don't Chyna9 11/21/14 12:03:44 PM
#20740   TCEL Weekly chart, notice that gap: sharky 11/21/14 11:45:57 AM
PostSubject